MSMarina Barbosa da Silva

Marina Barbosa da Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina Barbosa da Silva has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CRF1 receptor antagonists in congenital adrenal hyperplasia: A systematic review and meta-analysis of phase 2 open-label and phase 3 clinical trials

    by Mir Wajid Majeed, Emma Finnegan, Mariano Gallo Ruelas, Marco Quirós, Marina Barbosa da Silva, Issa Salha, Catalina Herrán-Fonseca, Helen Michaela de Oliveira, Melissa Chacón Quirós, Raheel Ahmed, et al.


  • Disease Progression in Pregnant Women with Relapsing–Remitting Multiple Sclerosis Treated with Fingolimod or Natalizumab Prior to Conception: A Systematic Review

    by Alice Campos Meneses, Felipe Perlingeiro Picard Flores da Cunha, Fernanda Cristina Poscai Ribeiro, Lucas de Deus Borges, Sarah Beatriz da Silva Koch, Wiviane Aparecida Dias Lopes, Áleff Mascarenhas Silva, Marina Barbosa da Silva, Aracelle Victor Do Carmo Faria


  • Open Access

    Avaliação do conhecimento sobre doação de medula óssea entre os estudantes de medicina da cidade de Guarujá - SP

    by Marianne Carneiro Barone Bomfim, Enrico Vieira de Medeiros e Figueira, Pedro Henrique Felix Tadei, Serena Pocas Moreno Silva, Marina Barbosa da Silva, Rafael Pacheco-Costa, Adriana Pina

    Introdução: A doação de medula óssea é um procedimento essencial para o tratamento de doenças hematológicas, como leucemias e linfomas. No entanto, a baixa adesão ao cadastro de doadores voluntários no Brasil, especialmente entre grupos estratégicos como estudantes de Medicina, reflete um possível déficit de conhecimento e conscientização sobre o tema. Objetivo: Avaliar o conhecimento dos estudantes de Medicina da cidade de Guarujá - SP sobre a doação de medula óssea, identificando lacunas informacionais e fatores que influenciam a disposição para o cadastro como doadores voluntários. Método: Estudo de corte transversal com abordagem quantitativa, realizado com 190 estudantes de Medicina de uma universidade particular da cidade de Guarujá – SP. Os dados foram coletados por meio de um questionário estruturado contendo questões sociodemográficas, conhecimento sobre o Registro Nacional de Doadores de Medula Óssea (REDOME), percepção do processo de doação e motivadores/barreiras para o cadastro. Os dados foram analisados de forma descritiva, com distribuição percentual das respostas. Resultados: Os achados revelaram que 56,84% dos estudantes desconheciam o REDOME e apenas 6,84% estavam cadastrados como doadores. Entre os principais motivos para não se cadastrarem estavam a falta de informação (37,89%) e o medo de complicações (23,68%). Apesar disso, 53,16% afirmaram já ter considerado a possibilidade de doar medula óssea. Barreiras emocionais e desinformação mostraram-se predominantes. A maioria dos estudantes era do sexo feminino (64,74%), entre 18 e 24 anos (78,42%) e solteira (69,47%). Conclusão: Os resultados evidenciam a necessidade de estratégias educativas voltadas ao público universitário da área da saúde, com inclusão do tema no currículo, campanhas informativas e facilitação do processo de cadastro. Tais medidas são essenciais para ampliar a base de doadores no país e fortalecer o papel dos futuros médicos na promoção da doação de medula óssea.

  • Efficacy and safety of galcanezumab for cluster headache preventive treatment: a systematic review and meta-analysis

    by Marina Barbosa da Silva, Domênica Baroni Coelho de Oliveira Ferreira, Cristian D. Mendieta, Hamilcar Pereira da Silva, Lívia Aguiar Nogueira-Rosa, Nathalia Moraes-Figueiredo

    Galcanezumab is a monoclonal antibody targeting the CGRP pathway and represents the latest disease-specific and mechanism-based therapeutic option for cluster headache (CH). We performed a systematic review and meta-analysis to evaluate the efficacy and safety of galcanezumab for CH. We searched PubMed, Embase, and Cochrane Library for studies implementing galcanezumab for episodic and chronic CH. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Reporting Guidelines for Meta-analyses of Observational Studies (MOOSE) guidelines. The primary outcome was efficacy, defined by a reduction from the baseline of at least 50% in the weekly frequency of CH attacks and the Patient Global Impression of Improvement scale (PGI-I). Secondary outcomes included treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). A total of 504 patients were included from 6 studies, of which 2 were RCTs. The follow-up period ranged from 3 weeks to 15 months. The mean age was 44.4 ± 10.2 years, with 24.4% female patients. Overall efficacy was 76.0% (95% CI 0.67-0.85), TEAEs were observed in 48.0% of patients (95% CI 0.25-0.72), and the most common were nasopharyngitis, local injection pain, and local injection swelling. TEAEs were, however, considerably higher within the 300 mg dose group compared with the 240 mg dose group, 80.0% (95% CI 0.65-0.87) versus 28.0% (95% CI 0.12-0.47), respectively. This meta-analysis suggests that galcanezumab is effective in reducing the number of CH attacks and can be considered a safe medication.


  • Open Access

    Comparison of Oxcarbazepine and Carbamazepine in the treatment of Trigeminal Neuralgia: a systematic review and meta-analysis

    by Cristian Mendieta, Marina Barbosa Da Silva, Livia Aguiar Nogueira-Rosa, Domênica Baroni Coelho de Oliveira Ferreira, Jhon Bocanegra-Becerra, Nathalia Moraes Figueiredo

    Oxcarbazepine (OXC) has demonstrated comparable efficacy to Carbamazepine (CBZ) in the treatment of Trigeminal neuralgia (TN), with the added benefit of fewer adverse events (AEs). Whether it can be used as a substitute for carbamazepine is yet to be verified. To address this, we conducted a comprehensive meta-analysis, exploring efficacy and adverse events in detail. We searched PubMed, Embase, Cochrane Library, and Google Scholar for studies comparing CBZ to OXC in patients with TN. The main outcomes were efficacy, AEs, frequency of neurological AEs, skin reactions, and alterations in laboratory parameters. Statistical analysis was performed using Review Manager 5.4.1. And the risk of bias was assessed using RoB-2 and ROBINS-I. We included 838 patients from three observational studies and two randomized clinical trials (RCTs). CBZ was used to treat TN in 445 (53.1%) patients. The CBZ group when compared with the OXC group had no significant difference in efficacy (OR:0.58; 95% Cl:0.14-2.40; p=0.45). Both groups had significant differences noted in AEs, with higher frequency observed in the CBZ group (OR:2.30; 95% Cl:1.49-3.54; p=0.0002). Similarly, there was a significant difference in neurological AEs (OR:2.76; 95% Cl:1.53-4.87; p=0.0007). OXC and CBZ demonstrated similar efficacy in treating trigeminal neuralgia. However, the consideration of adverse events may favor clinical decision-making to OXC due to its superiority. Nonetheless, more randomized controlled trials (RCTs) are necessary to confirm this conclusion in the future